Gluetacs Therapeutics Receives CDE IND Acceptance for First-in-Class Molecular Glue Degrader; Existing Investor Pangu Venture Capital Reinvests

Recently, the IND application for Gluetacs Therapeutics’ first molecular glue degrader product pipeline was accepted by the CDE, and existing shareholder Grains Valley Capital completed a capital increase.

BiaoXin Biomedical Technology (Shanghai) Co., Ltd. was founded in Shanghai in February 2020 by Academician Jiang Biao, a member of the International Eurasian Academy of Sciences and former Director of the Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, and Professor Yang Xiaobao, formerly of the Institute of Immunochemistry at ShanghaiTech University. The company focuses on developing novel oral small-molecule drugs using protein degradation technology and has established a robust pipeline of degrader candidates, dedicated to addressing unmet clinical needs. The team possesses extensive expertise across the entire workflow of protein degrader development, including AI-driven rational design and virtual screening of degraders, high-throughput digital cellular screening, optimization of oral druggability, quantitative proteomics validation, and in vivo pharmacological and toxicological assessment.

Dr. Yang Xiaobao, Founder, Chairman, and CEO of BiaoXin Biomedical Technology (Shanghai) Co., Ltd., stated: “We extend our gratitude to Beijing Grains Valley Capital Investment Co., Ltd. for witnessing and supporting the company’s growth since the angel round, and for its continued investment during the capital winter. We will continue to uphold our development philosophy of ‘innovation and breakthrough,’ aiming to accelerate the market entry of China’s innovative protein-degradation drugs to meet patients’ clinical needs.”

Li Lining, Partner in the Life Sciences Sector at Grains Valley Capital, stated: “Molecular glues and PROTACs are the two major categories of targeted protein degradation technologies based on the ubiquitin-proteasome system, and their mechanisms of action have been progressively validated in clinical trials. BiaoXin Biomedical is one of the few new drug R&D enterprises to simultaneously pursue both molecular glues and PROTACs. The company has accumulated extensive proprietary knowledge in the design and optimization of both classes of degraders, offers unique insights into combining their respective advantages, and has established a differentiated technology platform and pipeline portfolio. Grains Valley Capital will continue to support the company’s development, accelerate product R&D, and consolidate its leading position in the field of protein degradation.”

Grains Valley Capital, established in 2007, is an early-stage venture capital firm dedicated to investing in emerging industries. With a sound investment philosophy and model, the firm has consistently adhered to an investment approach centered on corporate core competitiveness since its inception. Upholding the core values of efficiently allocating social resources and growing alongside creative and innovative enterprises and entrepreneurs through shared challenges, Grains Valley Capital focuses its investments primarily on information technology, life sciences, artificial intelligence, and other sectors. The company currently manages assets exceeding RMB 4 billion. In the life sciences sector, it focuses on various innovative technology platforms, including new drug discovery platforms, novel drug modalities and innovative therapies, and omics-based molecular diagnostics.

Gluetacs Therapeutics is a biopharmaceutical company dedicated to the research and development of orally bioavailable small-molecule protein degraders. As the first biopharma startup incubated by the School of Immunity and Chemistry at ShanghaiTech University, it was established in February 2020 and commenced formal operations in March 2021. The company was founded and led by a team of scientists with extensive expertise in the field of protein degradation. Gluetacs Therapeutics owns proprietary development platforms for molecular glue degraders (GLUE) and dual-mechanism degraders (GLUETAC), featuring distinctive differentiated technological approaches and strategic development pathways. The company has independently established an AI-powered virtual screening platform, in vitro efficacy screening platform, pharmacokinetics platform, proteomics platform, and tumor animal efficacy model platform, thereby achieving a comprehensive end-to-end drug discovery and development system. Since commencing operations eighteen months ago, Gluetacs Therapeutics has fully demonstrated the capability of its GLUETACS™ platform to rapidly discover and advance pipeline candidates.